Abstract
Cannabis abuse is a common phenomenon among adolescents. The dominant psychoactive substance in Cannabis sativa is tetrahydrocannabinol (THC). However, in the past 40 years the content of the psychoactive ingredient THC in most of the preparations is not constant but has increased due to other breeding and culturing conditions. THC acts as the endocannabinoids at CB1 and CB2 receptors but pharmacologically can be described as a partial (not a pure) agonist. Recent evidence shows that activation of the CB1 receptor by THC can diminish the production of neuronal growth factor in neurons and affect other signalling cascades involved in synapsis formation. Since these factors play an important role in the brain development and in the neuronal conversion processes during puberty, it seems reasonable that THC can affect the adolescent brain in another manner than the adult brain. Accordingly, in adolescent cannabis users structural changes were observed with loss of grey matter in certain brain areas. Moreover, recent studies show different effects of THC on adolescent and adult brains and on behaviour. These studies indicate that early THC abuse can result in neuropsychological deficits. This review gives an overview over the present knowledge in this field.
References
1.
Dhein
S
, Schmelmer
K
, Guenther
J
, Salameh
A
. Aspects of methamphetamine abuse in adolescents and young adults in a Thuringian County
. Eur Addict Res
. 2018
;24
(2
):98
–105
. 2.
Werse
B
, Müller
O
, Carsten Schell
C
, Morgenstern
C
. Drogentrends in Frankfurt am Main
. Frankfurt
: Centre for Drug Research, Goethe-Universität
; 2010
. Available from:
https://www.uni-frankfurt.de/51785016/Jahresbericht_2010.pdf.3.
Die Drogenbeauftragte der Bundesregierung; Bundesministerium für Gesundheit: Drogen und Suchtbericht 2016. Available from: https://www.bundesregierung.de/Content/Infomaterial/BMG/_2902.html
.4.
Beck
F
, Guignard
R
, Richard
JB
. Epidemiological news in cannabis
. Rev Prat
. 2013 Dec
;63
(10
):1420
–4
.5.
Miller
PM
, Plant
M
. Drinking, smoking, and illicit drug use among 15 and 16 year olds in the United Kingdom
. BMJ
. 1996 Aug 17
;313
(7054
):394
–7
. 6.
Čecho
R
, Baška
T
, Švihrová
V
, Hudečková
H
. Legislative norms to control cannabis use in the light of its prevalence in Czech Republic, Poland, Slovakia, and Hungary
. Cent Eur J Public Health
. 2017 Dec
;25
(4
):261
–5
.7.
Grotenhermen
F
, Müller-Vahl
K
. The therapeutic potential of cannabis and cannabinoids
. Dtsch. Ärzteblatt Int
. 2012
;109
(29–30
):495
–501
. 8.
Die Drogenbeauftragte der Bundesregierung beim Bundesministerium für Gesundheit: Drogen und Suchtbericht 2019. Available from: https://www.drogenbeauftragte.de/fileadmin/dateien-dba/Drogenbeauftragte/4_Presse/1_Pressemitteilungen/2019/2019_IV.Q/DSB_2019_mj_barr.pdf
.9.
Grant
JE
, Chamberlain
SR
, Schreiber
L
, Odlaug
BL
. Neuropsychological deficits associated with cannabis use in young adults
. Drug Alcohol Depend
. 2012
;121
(1–2
):159
–62
. 10.
Battisti
RA
, Roodenrys
S
, Johnstone
SJ
, Pesa
N
, Hermens
DF
, Solowij
N
. Chronic cannabis users show altered neurophysiological functioning on Stroop task conflict resolution
. Psychopharmacology
. 2010
;212
(4
):613
–24
. 11.
McKetin
R
, Parasu
P
, Cherbuin
N
, Eramudugolla
R
, Anstey
KJ
. A longitudinal examination of the relationship between cannabis use and cognitive function in mid-life adults
. Drug Alcohol Depend
. 2016
;169
:134
–40
. 12.
Hirst
RB
, Watson
J
, S Rosen
A
, Quittner
Z
. Perceptions of the cognitive effects of cannabis use: a survey of neuropsychologists’ beliefs
. J Clin Exp Neuropsychol
. 2019
;41
(2
):133
–46
. 13.
Skalski
LM
, Towe
SL
, Sikkema
KJ
, Meade
CS
. Memory impairment in HIV-infected individuals with early and late initiation of regular marijuana use
. AIDS Behav
. 2018
;22
(5
):1596
–605
. 14.
Di Marzo
V
, Piscitelli
F
. The endocannabinoid system and its modulation by phytocannabinoids
. Neurotherapeutics
. 2015 Oct
;12
(4
):692
–8
. 15.
Zou
S
, Kumar
U
. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system
. Int J Mol Sci
. 2018 Mar 13
;19
(3
):E833
.16.
Bozkurt
TE
. Endocannabinoid system in the airways
. Molecules
. 2019 Dec 17
;24
(24
):E4626
. 17.
Oláh
A
, Szekanecz
Z
, Bíró
T
. Targeting cannabinoid signaling in the immune system: “high”-ly exciting questions, possibilities, and challenges
. Front Immunol
. 2017 Nov 10
;8
:1487
. 18.
Chiurchiù
V
, Battistini
L
, Maccarrone
M
. Endocannabinoid signalling in innate and adaptive immunity
. Immunology
. 2015 Mar
;144
(3
):352
–64
. 19.
Felder
CC
, Joyce
KE
, Briley
EM
, Mansouri
J
, Mackie
K
, Blond
O
, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors
. Mol Pharmacol
. 1995
;48
(3
):443
–50
.20.
Pertwee
RG
. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin
. Br J Pharmacol
. 2008
;153
(2
):199
–215
. 21.
Khanolkar
AD
, Abadji
V
, Lin
S
, Hill
WA
, Taha
G
, Abouzid
K
, et al. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand
. J Med Chem
. 1996
;39
(22
):4515
–9
. 22.
Hillard
CJ
, Manna
S
, Greenberg
MJ
, DiCamelli
R
, Ross
RA
, Stevenson
LA
, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1)
. J Pharmacol Exp Ther
. 1999
;289
(3
):1427
–33
.23.
Di Marzo
V
, Bisogno
T
, De Petrocellis
L
, Brandi
I
, Jefferson
RG
, Winckler
RL
, et al. Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor “hybrid” ligands
. Biochem Biophys Res Commun
. 2001
;281
: 444
–51
. 24.
Bowles
NP
, Karatsoreos
IN
, Li
X
, Vemuri
VK
, Wood
JA
, Li
Z
, et al. A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome
. Proc Natl Acad Sci U S A
. 2015
;112
(1
):285
–90
. 25.
Ross
RA
, Brockie
HC
, Stevenson
LA
, Murphy
VL
, Templeton
F
, Makriyannis
A
, et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630
. Br J Pharmacol
. 1999
;126
:665
–72
. 26.
Rinaldi-Carmona
M
, Barth
F
, Millan
J
, Derocq
JM
, Casellas
P
, Congy
C
, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor
. J Pharmacol Exp Ther
. 1998
;284
(2
):644
–50
.27.
Howlett
AC
, Abood
ME
. CB(1) and CB(2) receptor pharmacology
. Adv Pharmacol
. 2017
;80
:169
–206
. 28.
Kano
M
, Ohno-Shosaku
T
, Hashimotodani
Y
, Uchigashima
M
, Watanabe
M
. Endocannabinoid-mediated control of synaptic transmission
. Physiol Rev
. 2009 Jan
;89
(1
):309
–80
. 29.
Castillo
PE
, Younts
TJ
, Chávez
AE
, Hashimotodani
Y
. Endocannabinoid signaling and synaptic function
. Neuron
. 2012 Oct 4
;76
(1
):70
–81
. 30.
Barrie
N
, Manolios
N
. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease
. Eur J Rheumatol
. 2017 Sep
;4
(3
):210
–8
. 31.
Maccarrone
M
, Bab
I
, Bíró
T
, Cabral
GA
, Dey
SK
, Di Marzo
V
, et al. Endocannabinoid signaling at the periphery: 50 years after THC
. Trends Pharmacol Sci
. 2015 May
;36
(5
):277
–96
. 32.
Gruden
G
, Barutta
F
, Kunos
G
, Pacher
P
. Role of the endocannabinoid system in diabetes and diabetic complications
. Br J Pharmacol
. 2016 Apr
;173
(7
):1116
–27
. 33.
Lu
HC
, Mackie
K
. An introduction to the endogenous cannabinoid system
. Biol Psychiatry
. 2016 Apr 1
;79
(7
):516
–25
. 34.
Chua
JT
, Argueta
DA
, DiPatrizio
NV
, Kovesdy
CP
, Vaziri
ND
, Kalantar-Zadeh
K
, et al. Endocannabinoid system and the kidneys: from renal physiology to injury and disease
. Cannabis Cannabinoid Res
. 2019 Mar 13
;4
(1
):10
–20
. 35.
Tam
J
, Liu
J
, Mukhopadhyay
B
, Cinar
R
, Godlewski
G
, Kunos
G
. Endocannabinoids in liver disease
. Hepatology
. 2011 Jan
;53
(1
):346
–55
. 36.
Cascini
F
, Aiello
C
, Di Tanna
G
. Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis
. Curr Drug Abuse Rev
. 2012 Mar
;5
(1
):32
–40
.37.
McLaren
J
, Swift
W
, Dillon
P
, Allsop
S
. Cannabis potency and contamination: a review of the literature
. Addiction
. 2008 Jul
;103
(7
):1100
–9
. 38.
Freeman
TP
, Groshkova
T
, Cunningham
A
, Sedefov
R
, Griffiths
P
, Lynskey
MT
. Increasing potency and price of cannabis in Europe, 2006–16
. Addiction
. 2019 Jun
;114
(6
):1015
–23
. 39.
Dujourdy
L
, Besacier
F
. A study of cannabis potency in France over a 25 years period (1992–2016)
. Forensic Sci Int
. 2017 Mar
;272
:72
–80
. 40.
Rømer Thomsen
K
, Lindholst
C
, Thylstrup
B
, Kvamme
S
, Reitzel
LA
, Worm-Leonhard
M
, et al. Changes in the composition of cannabis from 2000–2017 in Denmark: analysis of confiscated samples of cannabis resin
. Exp Clin Psychopharmacol
. 2019 Aug
;27
(4
):402
–11
.41.
Niesink
RJ
, Rigter
S
, Koeter
MW
, Brunt
TM
. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15
. Addiction
. 2015 Dec
;110
(12
):1941
–50
. 42.
Chandra
S
, Lata
H
, ElSohly
MA
, Walker
LA
, Potter
D
. Cannabis cultivation: methodological issues for obtaining medical-grade product
. Epilepsy Behav
. 2017 May
;70
(Pt B
):302
–12
. 43.
ElSohly
MA
, Mehmedic
Z
, Foster
S
, Gon
C
, Chandra
S
, Church
JC
. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States
. Biol Psychiatry
. 2016
;79
(7
):613
–9
. 44.
Rigter
S
, Bossong
M
. THC-concentraties in wiet, nederwiet en hasj in Nederlandse coffeeshops (2018–2019)
. In: Drugs Informatie en Monitoring Systeem (DIMS), Programma Drug Monitoring and Policy
. Utrecht
: Trimbos-instituut
; 2019
. p. 2
–76
.45.
Lebel
C
, Beaulieu
C
. Longitudinal development of human brain wiring continues from childhood into adulthood
. J Neurosci
. 2011 Jul 27
;31
(30
):10937
–47
. 46.
Gogtay
N
, Giedd
JN
, Lusk
L
, Hayashi
KM
, Greenstein
D
, Vaituzis
AC
, et al. Dynamic mapping of human cortical development during childhood through early adulthood
. Proc Natl Acad Sci U S A
. 2004 May 25
;101
(21
):8174
–9
. 47.
Colver
A
, Longwell
S
. New understanding of adolescent brain development: relevance to transitional healthcare for young people with long term conditions
. Arch Dis Child
. 2013 Nov
;98
(11
):902
–7
. 48.
Barnea-Goraly
N
, Menon
V
, Eckert
M
, Tamm
L
, Bammer
R
, Karchemskiy
A
, et al. White matter development during childhood and adolescence: a cross-sectional diffusion tensor imaging study
. Cereb Cortex
. 2005 Dec
;15
(12
):1848
–54
. 49.
Abitz
M
, Nielsen
RD
, Jonesz
EG
, Lauren
H
, Pakkenberg
NGB
. Excess of neurons in the human newborn mediodorsal thalamus compared with that of the adult
. Cereb Cortex
. 2007
;17
: 2573
–8
. 50.
Kaag
AM
, Schulte
MHJ
, Jansen
JM
, van Wingen
G
, Homberg
J
, van den Brink
W
, et al. The relation between gray matter volume and the use of alcohol, tobacco, cocaine and cannabis in male polysubstance users
. Drug Alcohol Depend
. 2018 Jun 1
;187
:186
–94
. 51.
Whitaker
KJ
, Vértes
PE
, Romero-Garcia
R
, Váša
F
, Moutoussis
M
, Prabhu
G
, et al. Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome
. Proc Natl Acad Sci U S A
. 2016 Aug 9
;113
(32
):9105
–10
. 52.
Giedd
JN
, Blumenthal
J
, Jeffries
NO
, Castellanos
FX
, Liu
H
, Zijdenbos
A
, et al. Brain development during childhood and adolescence: a longitudinal MRI study
. Nat Neurosci
. 1999 Oct
;2
(10
):861
–3
. 53.
Lisano
JK
, Kisiolek
JN
, Smoak
P
, Phillips
KT
, Stewart
LK
. Chronic cannabis use and circulating biomarkers of neural health, stress, and inflammation in physically active individuals
. Appl Physiol Nutr Metab
. 2019 Jul 18
;45
(3
):258
–63
. 54.
Angelucci
F
, Ricci
V
, Spalletta
G
, Pomponi
M
, Tonioni
F
, Caltagirone
C
, et al. Reduced serum concentrations of nerve growth factor, but not brain-derived neurotrophic factor, in chronic cannabis abusers
. Eur Neuropsychopharmacol
. 2008 Dec
;18
(12
):882
–7
. 55.
Jockers-Scherübl
MC
, Matthies
U
, Danker-Hopfe
H
, Lang
UE
, Mahlberg
R
, Hellweg
R
. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients
. J Psychopharmacol
. 2003 Dec
;17
(4
):439
–45
. 56.
Jockers-Scherübl
MC
, Danker-Hopfe
H
, Mahlberg
R
, Selig
F
, Rentzsch
J
, Schürer
F
, et al. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse
. Neurosci Lett
. 2004 Nov 16
;371
(1
):79
–83
. 57.
Jockers-Scherübl
MC
, Rentzsch
J
, Danker-Hopfe
H
, Radzei
N
, Schürer
F
, Bahri
S
, et al. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse
. Neurosci Lett
. 2006 Jun 12
;400
(3
):262
–6
. 58.
Bracci-Laudiero
L
, Aloe
L
, Levi-Montalcini
R
, Buttinelli
C
, Schilter
D
, Gillessen
S
, et al. Multiple sclerosis patients express increased levels of b-nerve growth factor in cerebrospinal fluid
. Neurosci Lett
. 1992
;147
:9
–12
. 59.
Bracci-Laudiero
L
, Aloe
L
, Levi-Montalcini
R
, Galeazzi
M
, Schilter
D
, Scully
JL
, et al. Increased levels of NGF in sera of systemic lupus erythematosus patients
. NeuroReport
. 1993
;4
:563
–5
. 60.
Aalto
K
, Korhonen
L
, Lahdenne
P
, Pelkonen
P
, Lindholm
D
. Nerve growth factor in serum of children with systemic lupus erythematosus is correlated with disease activity
. Cytokine
. 2002
;20
:136
–9
. 61.
Keimpema
E
, Tortoriello
G
, Alpár
A
, Capsoni
S
, Arisi
I
, Calvigioni
D
, et al. Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons
. Proc Natl Acad Sci U S A
. 2013 Jan 29
;110
(5
):1935
–40
. 62.
Wang
ZY
, McDowell
T
, Wang
P
, Alvarez
R
, Gomez
T
, Bjorling
DE
. Activation of CB1 inhibits NGF-induced sensitization of TRPV1 in adult mouse afferent neurons
. Neuroscience
. 2014 Sep 26
;277
:679
–89
. 63.
Augustin
SM
, Lovinger
DM
. Functional relevance of endocannabinoid-dependent synaptic plasticity in the central nervous system
. ACS Chem Neurosci
. 2018 Sep 19
;9
(9
):2146
–61
. 64.
Blest-Hopley
G
, O’Neill
A
, Wilson
R
, Giampietro
V
, Bhattacharyya
S
. Disrupted parahippocampal and midbrain function underlie slower verbal learning in adolescent-onset regular cannabis use
. Psychopharmacology
. 2019 Dec 9
. Online ahead of print
. 65.
Miguez
MJ
, Chan
W
, Espinoza
L
, Tarter
R
, Perez
C
. Marijuana use among adolescents is associated with deleterious alterations in mature BDNF
. AIMS Public Health
. 2019 Jan 17
;6
(1
):4
–14
.66.
Meier
MH
, Schriber
RA
, Beardslee
J
, Hanson
J
, Pardini
D
. Associations between adolescent cannabis use frequency and adult brain structure: a prospective study of boys followed to adulthood
. Drug Alcohol Depend
. 2019 Sep 1
;202
:191
–9
. 67.
Di Forti
M
, Quattrone
D
, Freeman
TP
, Tripoli
G
, Gayer-Anderson
C
, Quigley
H
, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
. Lancet Psychiatry
. 2019 May
;6
(5
):427
–36
.68.
Harvey
MA
, Sellman
JD
, Porter
R
, Frampton
CM
. The relationship between non‐acute use of cannabis and cognition
. Drug Alcohol Rev
. 2007
;26
:309
–19
. 69.
Legleye
S
, Obradovic
I
, Janssen
E
, Spilka
S
, Le Névzet
O
, Beck
F
. Influence of cannabis use trajectories, grade repetition and family background on the school-dropout rate at the age of 17 years in France
. Eur J Public Health
. 2010
;20
:157
–63
. 70.
Horwood
JL
, Fergusson
DM
, Hayatbakhsh
MR
, Najman
JM
, Coffey
C
, Patton
GC
, et al. Cannabis use and educational achievement: findings from three Australasian cohort studies
. Drug Alcohol Depend
. 2010
;110
:247
–53
. 71.
Degenhardt
L
, Coffey
C
, Carlin
JB
, Swift
W
, Moore
E
, Patton
GC
. Outcomes of occasional cannabis use in adolescence: 10‐year follow‐up study in Victoria, Australia
. Br J Psychiatry
. 2010
;196
:290
–5
. 72.
Fergusson
DM
, Horwood
JL
, Beautrais
AL
. Cannabis and educational achievement
. Addiction
. 2003
;98
:1681
–92
. 73.
Fergusson
DM
, Boden
JM
. Cannabis use and later life outcomes
. Addiction
. 2008
;103
:969
–76
. 74.
Hyggen
C
. Does smoking cannabis affect work commitment?
Addiction
. 2012
;107
:1309
–15
. 75.
Danielsson
AK
, Falkstedt
D
, Hemmingsson
T
, Allebeck
P
, Agardh
E
. Cannabis use among Swedish men in adolescence and the risk of adverse life course outcomes: results from a 20 year-follow-up study
. Addiction
. 2015 Nov
;110
(11
):1794
–802
. 76.
Daniel
JZ
, Hickman
M
, Macleod
J
, Wiles
N
, Lingford-Hughes
A
, Farrell
M
, et al. Is socioeconomic status in early life associated with drug use? A systematic review of the evidence
. Drug Alcohol Rev
. 2009 Mar
;28
(2
):142
–53
. 77.
Sachs
J
, McGlade
E
, Yurgelun-Todd
D
. Safety and toxicology of cannabinoids
. Neurotherapeutics
. 2015 Oct
;12
(4
):735
–46
. 78.
Schoeler
T
, Bhattacharyya
S
. The effect of cannabis use on memory function: an update
. Subst Abuse Rehabil
. 2013 Jan 23
;4
:11
–27
. 79.
Benbadis
SR
, Sanchez-Ramos
J
, Bozorg
A
, Giarratano
M
, Kalidas
K
, Katzin
L
, et al. Medical marijuana in neurology
. Expert Rev Neurother
. 2014 Dec
;14
(12
):1453
–65
. 80.
McCormick
MA
, Shekhar
A
. Review of marijuana use in the adolescent population and implications of its legalization in the United States
. J Drug Metabol Toxicol
. 2014
;5
:2
.81.
Volkow
ND
, Baler
RD
, Compton
WM
, Weiss
SR
. Adverse health effects of marijuana use
. N Engl J Med
. 2014 Jun 5
;370
(23
):2219
–27
. 82.
Zalesky
A
, Solowij
N
, Yücel
M
, Lubman
DI
, Takagi
M
, Harding
IH
, et al. Effect of long-term cannabis use on axonal fibre connectivity
. Brain
. 2012 Jul
;135
(Pt 7
):2245
–55
. 83.
Meier
MH
, Caspi
A
, Ambler
A
, Harrington
H
, Houts
R
, Keefe
RS
, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife
. Proc Natl Acad Sci U S A
. 2012 Oct 2
;109
(40
):E2657
–64
. 84.
James
A
, James
C
, Thwaites
T
. The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review
. Psychiatry Res
. 2013 Dec 30
;214
(3
):181
–9
. 85.
Rogeberg
O
. Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status
. Proc Natl Acad Sci U S A
. 2013
;110
:4251
–4
. 86.
Pope
HG
Jr, Gruber
AJ
, Hudson
JI
, Cohane
G
, Huestis
MA
, Yurgelun-Todd
D
. Early-onset cannabis use and cognitive deficits: what is the nature of the association?
Drug Alcohol Depend
. 2003
;69
:303
–10
. 87.
Gruber
SA
, Sagar
KA
, Dahlgren
MK
, Racine
M
, Lukas
SE
. Age of onset of marijuana use and executive function
. Psychol Addictive Behav
. 2011
;26
(3
):496
–506
. 88.
Ehrenreich
H
, Rinn
T
, Kunert
HJ
, Moeller
MR
, Poser
W
, Schilling
L
, et al. Specific attentional dysfunction in adults following early start of cannabis use
. Psychopharmacol
. 1999
;142
:295
–301
. 89.
Mensen
VT
, Vreeker
A
, Nordgren
J
, Atkinson
A
, de la Torre
R
, Farré
M
, et al. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis
. Psychopharmacology
. 2019 Sep
;236
(9
):2677
–85
. 90.
Crane
NA
, Schuster
RM
, Fusar-Poli
P
, Gonzalez
R
. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences and sex differences
. Neuropsychol Rev
. 2013
;23
:117
–37
. 91.
Crane
NA
, Schuster
RM
, Mermelstein
RJ
, Gonzalez
R
. Neuropsychological sex differences associated with age of initiated use among young adult cannabis users
. J Clin Exp Neuropsychol
. 2015
;37
:389
–401
. 92.
Rubino
T
, Prini
P
, Piscitelli
F
, Zamberletti
E
, Trusel
M
, Melis
M
, et al. Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex
. Neurobiol Dis
. 2015 Jan
;73
:60
–9
. 93.
Prini
P
, Rusconi
F
, Zamberletti
E
, Gabaglio
M
, Penna
F
, Fasano
M
, et al. Adolescent THC exposure in female rats leads to cognitive deficits through a mechanism involving chromatin modifications in the prefrontal cortex
. J Psychiatry Neurosci
. 2018 Mar
;43
(2
):87
–101
. 94.
Zamberletti
E
, Gabaglio
M
, Grilli
M
, Prini
P
, Catanese
A
, Pittaluga
A
, et al. Long-term hippocampal glutamate synapse and astrocyte dysfunctions underlying the altered phenotype induced by adolescent THC treatment in male rats
. Pharmacol Res
. 2016 Sep
;111
:459
–70
. 95.
Schneider
M
, Koch
M
. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats
. Neuropsychopharmacology
. 2003
;28
(10
):1760
–89
. 96.
Renard
J
, Krebs
MO
, Jay
TM
, Le Pen
G
. Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison
. Psychopharmacology
. 2013
;225
(4
):781
–90
. 97.
Renard
J
, Rushlow
WJ
, Laviolette
SR
. What can rats tell us about adolescent cannabis exposure? Insights from preclinical research
. Can J Psychiatry
. 2016 Jun
;61
(6
):328
–34
. 98.
Steel
RW
, Miller
JH
, Sim
DA
, Day
DJ
. Learning impairment by Δ(9)-tetrahydrocannabinol in adolescence is attributable to deficits in chunking
. Behav Pharmacol
. 2011 Dec
;22
(8
):837
–46
. 99.
Miller
ML
, Chadwick
B
, Dickstein
DL
, Purushothaman
I
, Egervari
G
, Rahman
T
, et al. Adolescent exposure to Δ(9)-tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons
. Mol Psychiatry
. 2019 Apr
;24
(4
):588
–600
.100.
Bruijnzeel
AW
, Knight
P
, Panunzio
S
, Xue
S
, Bruner
MM
, Wall
SC
, et al. Effects in rats of adolescent exposure to cannabis smoke or THC on emotional behavior and cognitive function in adulthood
. Psychopharmacology
. 2019 Sep
;236
(9
):2773
–84
. 101.
Ellgren
M
, Artmann
A
, Tkalych
O
, Gupta
A
, Hansen
HS
, Hansen
SH
, et al. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects
. Eur Neuropsychopharmacol
. 2008 Nov
;18
(11
):826
–34
. 102.
Wilson
J
, Freeman
TP
, Mackie
CJ
. Effects of increasing cannabis potency on adolescent health
. Lancet Child Adolesc Health
. 2019 Feb
;3
(2
):121
–8
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
